We hypothesized that dysregulation of multiple downstream RAS effector pathways drives treatment resistance in GBM through co-activation of mTOR and ERK signaling, and that dual inhibition of these pathways would be effective in a subset of genetically defined GBM. The gene discussed is MTOR; the disease is glioblastoma.